Focus on ASCO presentation on June 1 for full data and any regulatory updates. The positive combination data supports azenosertib's broader potential, but the stock's history of large post-event reversals suggests caution on extended holding.
ZNTL drugs
ZNTL drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 22 $4.06entry
- T+1 · 6mo ago −2.46%α −3.05% · $3.96
- T+5 · 6mo ago −1.97%α −3.63% · $3.98
- T+20 · 5mo ago −8.87%α −7.45% · $3.70
- T+60 · 3mo ago −9.36%α −12.55% · $3.68
Price Chart
How similar events traded
Executive Summary
Zentalis announced positive Phase 1b data for azenosertib plus paclitaxel in platinum-resistant ovarian cancer, with 39% ORR and 7.3-month median PFS in all-comers, and 50% ORR at the 250 mg intermittent dose. The data will be presented at ASCO 2026. The company also reported a Q1 2026 EPS miss of $-0.50 versus consensus $-0.46, though this is secondary for a pre-revenue biotech.
Key Financial Metrics
Key Facts
- Phase 1b MUIR trial of azenosertib + paclitaxel showed 39% ORR and 7.3-month median PFS in all-comer PROC (n=46).
- At the 250 mg 5:2 intermittent dose (n=12), ORR was 50% with median DOR of 9.2 months.
- Clinical activity was comparable in Cyclin E1-positive and negative patients.
- Manageable safety: Grade ≥3 neutropenia 30.4%, anemia 19.6%.
- Data to be presented at ASCO 2026 on June 1.
- Q1 2026 EPS of -$0.50 missed consensus of -$0.46 (-8.7% miss).
Financial Impact
Clinical data positive but early; EPS miss of $0.04 is immaterial for pre-revenue biotech; stock likely driven by ASCO data.
Risk Factors
- Phase 1b data not yet confirmed in larger Phase 3 trials.
- Competition from other WEE1 inhibitors and chemotherapy combos.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299814 |
Track record
18 reports on ZNTL
5 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +51.42% at T+60 after the Aug 14, 2026 report. 6 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 4/10 Entry $1.62 Now $1.60 −1.23% settles Feb 12
- Nov 9, 20267d ago 8-K Bearish 5/10 Entry $1.80 Now $1.60 +11.11% settles Feb 8
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $2.06 Now $1.60 −22.33% settles Jan 26
- Oct 18, 202629d ago Press Release Bullish 7/10 Entry $2.30 Now $1.60 −30.43% settles Jan 14
- Oct 1, 20266w ago Press Release Neutral 2/10 Entry $2.52 Now $1.60 −36.51% settles Dec 29
- Aug 14, 202613w ago 8-K Bearish 6/10 Entry $3.71 to $1.80 Now $1.60 +56.82% ▲ +51.42% +48.47% vs SPY
- Aug 13, 202613w ago Press Release Bearish 6/10 Entry $3.56 to $1.74 Now $1.60 +55.06% ▲ +51.12% +48.08% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.75 to $4.03 Now $1.60 −57.33% ▲ +7.47% +4.20% vs SPY
- Jun 1, 202624w ago Press Release Neutral 2/10 Entry $3.95 to $3.89 Now $1.60 −59.49% ▼ −1.52% −2.64% vs SPY
- May 21, 202625w ago Press Release Bullish 6/10 Viewing Entry $4.06 to $3.68 Now $1.60 −60.59% ▼ −9.36% −12.55% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers